A recent Phase 2 study, published in the journal Bone Marrow Transplantation, evaluated Mozobil’s (plerixafor) ability to mobilize stem cells from the bone marrow into the blood without increasing the mobility of tumor cells in multiple myeloma patients.

One common treatment option available to eligible myeloma patients is high dose chemotherapy followed by autologous stem cell transplantation. Before chemotherapy, the patient’s own stem cells are collected by peripheral blood apheresis, which looks and feels similar to a routine blood donation, and then the stem cells are transplanted back after chemotherapy.

For …

The Committee for Human Medicinal Products of the European Medicines Agency has recommended that the stem cell transplant drug Mozobil (plerixafor) be approved for use in the European Union.

Mozobil is used for stem cells transplants in patients with blood cancers, specifically non-Hodgkin’s lymphoma and multiple myeloma. Combined with other drugs that stimulate the body's production of stem cells, Mozobil helps move stem cells from the bone marrow into the bloodstream, where they can be collected for subsequent transplants.

Traditionally, the collection of stem cells for transplantation has been a process that extends …

A new study in the journal Blood shows that adding Mozobil (plerixafor) to Neupogen (filgrastim) prior to stem cell harvesting significantly increases harvest efficiency.

Mozobil is a new drug designed to mobilize stem cells from the bone marrow into the bloodstream, where they can be collected. Neupogen, which is commonly given prior to stem cell harvesting, stimulates the body to make white blood cells.

When given together, Mozobil and Neupogen have been shown to increase harvest efficiency in myeloma patients prior to autologous peripheral stem cell transplantation. The U.S. Food and Drug Administration …

The U.S. Food and Drug Administration has approved Genzyme’s Mozobil (plerixafor injection), a drug that mobilizes hematopoietic stem cells (HSCs) from the bone marrow into the bloodstream. Mozobil has been approved for non-Hodgkin’s Lymphoma and multiple myeloma.

Mozobil is a small molecule CXCR4 chemokine receptor antagonist. The CXCR4 receptors are responsible for holding HSCs in bone marrow. These stem cells give rise to all blood types and can be used in cancer treatment. CXCR4 antagonists mobilize HSCs in the bloodstream. HSCs are then collected for autologous stem cell transplants, a …